Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
A pharmacological approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small molecule inhibitors has the potential to provide novel cancer therapies for clinical use. Achieving high levels of selectivity for Cdk4/6, versus other ATP-dependent kinases, presents a significant challenge. The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks. It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro. This selectivity profile is recapitulated in cells where the most selective inhibitors create a G(1) block at concentrations up to 100-fold the IC(50) for cell proliferation. On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
1 retracted
Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
Davis, S. T., Benson, B. G., Bramson, H. N., Chapman, D. E., Dickerson, S. H., Dold, K. M., Eberwein, D. J., Edelstein, M., Frye, S. V., Gampe, R. T., et al. (2001) · Science · doi:10.1126/science.291.5501.134 · Cited by 166
RetractedThe RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Synthesis of Macroporous Minerals with Highly Ordered Three-Dimensional Arrays of Spheroidal Voids
Holland, B. T., Blanford, C. F., & Stein, A. (1998) · Science · doi:10.1126/science.281.5376.538 · Cited by 1,484
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E. M., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., et al. (1999) · Nature Cell Biology · doi:10.1038/9035 · Cited by 809
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues
Veselý, J., Havliček, L., Strnad, M., Blow, J. J., Donella‐Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., et al. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00771.x · Cited by 632
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Research works printed but not linked: 46
- Fisher P. M., 2003, Expert. Opin. Investig. Drugs, 12, 970
- Fisher P. M, 2001, Curr. Opin. Drug Discuss. Dev., 4, 634
- Fry D. W., 2000, Curr. Opin. Oncol., Endocrine Metab. Invest. Drugs, 2, 59
- Gray N., 1999, Curr. Med. Chem., 6, 875
- Fry D. W., 2001, J. Biol. Chem., 276, 16623
- Wang S., 2001, Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry
- Chang Y.-T., 1999, Chem. Biol., 6, 375
- Schow S. R., 1997, Bioorg. Med. Chem. Lett., 7, 2702
- Zaharevitz D. W., 1999, Cancer Res., 59, 2569
- Gussio R., 2000, Anti-Cancer Drug Des., 15, 66
- Kunick C., 2000, Bioorg. Med. Chem. Lett., 10, 569, 10.1016/S0960-894X(00)00048-2 · DOI
- Tang J., 2003, Bioorg. Med. Chem. Lett., 13, 2988
- Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 2408
- Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 1136
- Song Y., 2002, Bioorg. Med. Chem. Lett., 12, 1132
- Kim K. S., 2002, J. Med. Chem., 45, 3927
- Furet P., 2002, Bioorg. Med. Chem. Lett., 12, 224
- Sielecki T. M., 2001, Bioorg. Med. Chem. Lett., 11, 1160
- Sasaki S., 1998, Bioorg. Med. Chem. Lett., 8, 1022
- Seong Y.-S., 2003, Cancer Res., 63, 7391
- Kim K. S., 2000, J. Med Chem., 43, 4134
- Li X., 2003, Bioorg. Med. Chem. Lett., 13, 1942
- Liu J.-J., 2003, Bioorg. Med. Chem. Lett., 13, 2468
- Yue E. W., 2002, J. Med. Chem., 45, 5248
- Lane M. E., 2001, Cancer Res., 61, 6177
- Andreani A., 2000, Anti-Cancer Drug Des., 15, 452
- Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3839
- Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3846
- Zhu G., 2003, Bioorg. Med. Chem. Lett., 13, 1235
- Ryu C.-K., 2000, Bioorg. Med. Chem. Lett., 10, 464
- Honma T., 2001, J. Med. Chem., 44, 4627
- Honma T., 2001, J. Med. Chem., 44, 4640
- Jeong H.-W., 2000, Bioorg. Med. Chem. Lett., 10, 1822
- Zhu G., 2003, J. Med. Chem., 46, 2030
- Bartek J., 2003, Biochem. J., 371, 204
- Bartkova J., 1997, Prog. Cell Cycle Res., 3, 220
- Hall M., 1996, Adv. Cancer Res., 68, 108
- Misra R. N., 2004, Chem
- Kelland L. R., 2000, Exp. Opin. Invest. Drugs, 9, 2911
- Chao S.-H., 2001, J. Biol. Chem., 276, 31799
- Chao S.-H., 2000, J. Biol. Chem., 275, 28348
- Tetsu O., 2003, Cancer Cell, 2, 245
- Fry D. W., 2004, Mol. Cancer Ther., 3, 1437
- Meyerson M., 1994, Mol. Cell Biol., 14, 2086
- Fry D. W., 1994, Anticancer Drug Des., 9, 351
- Fry D. W., 1997, Biochem. Pharmacol., 54, 887
Cited by
Items 301–400 of 555
Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21
Mortoglou, M., Miralles, F., Mould, R. R., Sengupta, D., & Onganer, P. U. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151318 · Cited by 18
Locatelli, G., Bosotti, R., Ciomei, M., Brasca, M. G., Calogero, R., Mercurio, C., Fiorentini, F., Bertolotti, M., Scacheri, E., Scaburri, A., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1163 · Cited by 17
Kuminek, G., Salehi, N., Waltz, N. M., Sperry, D. C., Greenwood, D. E., Hate, S. S., & Amidon, G. E. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00545 · Cited by 15
Inhibition of USP10 induces myeloma cell apoptosis by promoting cyclin D3 degradation
Xu, Y., Zeng, K., Ren, Y., Mao, C.-Y., Ye, Y., Zhu, X.-T., Sun, Z., Cao, B., Zhang, Z.-B., Xu, G., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01083-w · Cited by 15
“Moreover, given the nature of the CCND3/CDK4/6 complex, we found Spautin-1, the inhibitor of USP10, synergizes with the anti-MM activity of Palbociclib, a CKD4/ 6 specific inhibitor [34].”
BackgroundWang, F., Ma, Z., Li, Y., Zhu, S., Xiao, Z., Zhang, H., & Wang, Y. (2011) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2011.06.006 · Cited by 15
Recent Progress of Cyclin-Dependent Kinase Inhibitors as Potential Anticancer Agents
Li, T., Weng, T., Zuo, M., Wei, Z., Chen, M., & Li, Z. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0129 · Cited by 15
Wang, D., Sun, Y., Li, W., Ye, F., Zhang, Y., Guo, Y., Zhang, D., & Suo, J. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3460 · Cited by 15
“It has emerged as a promising agent for cell cycle-based therapy, due to its ability to rapidly and specifically inhibit CDK4 and CDK6 activity.”
InfluentialManzari, M. T., Anderson, G. R., Lin, K., Soderquist, R. S., Çakır, M., Zhang, M. Y., Moore, C. E., Skelton, R. N., Fevre, M., Li, X., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw9162 · Cited by 15
Fatahala, S. S., Sayed, A. I., Mahgoub, S., Taha, H., El-Sayed, M.-I. K., Shehry, M. F. E., Awad, S. M., & El-Hameed, R. H. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111957 · Cited by 21
“Furthermore, pyrimidine analogs have been developed as cyclin-dependent kinase inhibitors [17,18], like CDK2A inhibitors [19] or checkpoint kinase inhibitors [20], as revealed in Figure 1.”
BackgroundmTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL
Vo, T.-T. T., Lee, J. S., Nguyen, D. M., Lui, B., Pandori, W., Khaw, A., Mallya, S., Lu, M., Müschen, M., Konopleva, M. Y., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0024 · Cited by 17
“To determine whether cell-cycle inhibition was sufficient to protect B-ALL cells frommaintenance drugs, we used the CDK4/6 inhibitor, palbociclib (32), to selectively inhibit cell cycling Figure 3.”
MethodOf Model Pets and Cancer Models: An Introduction to Mouse Models of Cancer
Lunardi, A., Nardella, C., Clohessy, J. G., & Pandolfi, P. P. (2013) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069757 · Cited by 16
“GEMMs are often used to determine whether the potential target of a new compound is indeed a key factor for tumor cell survival, proliferation, or migration (Martin et al. 2005; Toogood et al. 2005).”
Targeting CDK2 and other novel cell cycle targets for breast cancer therapy
Chen, M., Luo, L., Massoumi, N. L., & Keyomarsi, K. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2537412 · Cited by 15
“CDK4/6 inhibitors (CDK4/6i), including palbociclib, ribociclib, and abemaciclib, selectively target CDK4 and CDK6 to inhibit cell cycle progression [64–66].”
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor
Gallego, G. M., Palmer, C. L., Orr, S. T. M., Bernier, L., Chen, P., Cho-Schultz, S., Deal, J. G., Dress, K. R., Edwards, M. P., Jalaie, M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02137 · Cited by 14
Targeting cell cycle kinases and kinesins in anticancer drug development
Yap, T. A., Molife, L. R., Blagden, S. P., & Bono, J. S. D. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.4.539 · Cited by 14
“PD-0332991 (Pfizer Global Research, New York) is a new generation CDK inhibitor of the pyridopyrimidine class and a selective inhibitor of Cdk4 and Cdk6 [53,54].”
BackgroundPickering, J., Chinnaiya, K., & Towers, M. (2019) · eLife · doi:10.7554/elife.47625 · Cited by 14
Advances in drug development for targeted therapies for glioblastoma
Ge, Y., Wang, Y., Chen, J., Zheng, W., Liu, C., Chen, S., Wang, L., Luo, J., & Li, Z. (2020) · Medicinal Research Reviews · doi:10.1002/med.21676 · Cited by 14
An In Silico Approach for Potential Natural Compounds as Inhibitors of Protein CDK1/Cks2
Saikat, A. S. M. (2021) · International Electronic Conference on Synthetic Organic Chemistry (ECSOC) · doi:10.3390/ecsoc-25-11721 · Cited by 14
Chemical fragment-based CDK4/6 inhibitors prediction and web server
Wang, L., Li, Y., Xu, M., Pang, X., Liu, Z., Tan, W., & Xu, J. (2016) · RSC Advances · doi:10.1039/c5ra23289a · Cited by 16
Emerging Therapies for Breast Cancer
Goel, S., & Chandarlapaty, S. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041333 · Cited by 17
Guo, L., Hu, Y., Chen, X., Li, Q., Wei, B., & Ma, X. (2019) · Cancer Medicine · doi:10.1002/cam4.1970 · Cited by 14
Active RB causes visible changes in nuclear organization
Krishnan, B., Yasuhara, T., Rumde, P. H., Stanzione, M., Lu, C., Lee, H., Lawrence, M. S., Zou, L., Nieman, L. T., Sanidas, I., et al. (2022) · The Journal of Cell Biology · doi:10.1083/jcb.202102144 · Cited by 13
Mascarenhas, N. M., & Ghoshal, N. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci8000343 · Cited by 13
Drug Targeting of Oncogenic Pathways in Melanoma
Fecher, L. A., Amaravadi, R. K., Schuchter, L. M., & Flaherty, K. T. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.004 · Cited by 14
An Inducible, Isogenic Cancer Cell Line System for Targeting the State of Mismatch Repair Deficiency
Bailis, J. M., Gordon, M. L., Gurgel, J. L., Komor, A. C., Barton, J. K., & Kirsch, I. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078726 · Cited by 13
“The CDK4/6 inhibitor PD-0332991 [22], used as a positive control for senescence assays, was synthesized according to published methods.”
MethodDevelopment and Strategies of CDK4/6 Inhibitors
Chen, P., Xu, Y., Li, X., Yao, H., & Lin, K. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0062 · Cited by 14
El‐Sayed, W. A., Mohamed, A. M., Khalaf, H. S., El-kady, D. S., & El‐Manawaty, M. A. (2017) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2017.70901 · Cited by 13
“A variety of pyrimidine derivatives fused with other heterocycles has been found as anticancer agents used in clinics or in clinical trials (VanderWel et al., 2005; Toogood et al., 2005; Palmer et al., 2005; Malagu et al., 2009; Zhao et al., 2007; Hafez and El-Gazzar, 2009; Shawali et al., 2010).”
BackgroundNoor, R., Zahoor, A. F., Mansha, A., Khan, S. G., Haq, A. U., Ahmad, S., Al‐Hussain, S. A., Irfan, A., & Zaki, M. E. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076692 · Cited by 12
“Kenpaullone and alsterpaullone (1a,b) [5] have demonstrated the anticancer activity and CDK inhibitory activity [6,7].”
BackgroundZhou, J. W., Yan, G. G., Cluckey, D., Meade, C., Ruth, M., Sorm, R., Tam, A. S. P., Lim, S., Petridis, C., Lin, L., et al. (2023) · Antibodies · doi:10.3390/antib12030053 · Cited by 14
“Adding potent CDK4/6 inhibitors such as Palbociclib [38] to the cell culture did not result in a meaningful expression titer enhancement at the concentrations of 1–40 μM .”
BackgroundInfluentialTrouth, A., Ravichandran, K., Gafken, P. R., Martire, S., Boyle, G. E., Veronezi, G. M. B., La, V. E., Namciu, S. J., Banaszynski, L. A., Sarthy, J. F., et al. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003119 · Cited by 14
“The CDK4/6 inhibitor Palbociclib restricts cells in the G1 phase via inhibition of the CDK4/6-cyclin D1-Rb pathway [26,27].”
Jiang, C., Ye, Y., Kang, W., Yang, J., He, Z., Cao, Q., Lian, C., Xing, Y., Yang, Q., Zhao, J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01686 · Cited by 12
Yuan, H., Liu, H., Tai, W., Wang, F., Zhang, Y., Yao, S., Ran, T., Lü, S., Ke, Z., Xiong, X., et al. (2013) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2013.815655 · Cited by 12
Solid-phase synthesis of pyrido[2,3-d]pyrimidin-7-ones
Angiolini, M., Fusar-Bassini, D., Gude, M., & Menichincheri, M. (2005) · Tetrahedron Letters · doi:10.1016/j.tetlet.2005.10.030 · Cited by 12
O’Rourke, R. L., & Garner, A. L. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00674 · Cited by 13
Mortlock, A. A., Foote, K. M., Kettle, J. G., & Aquila, B. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.11033-9 · Cited by 16
Delgado, M., & Chambers, T. C. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1496746 · Cited by 15
“A leading candidate is the highly selective CDK4/6 inhibitor palbociclib (PCB) [24].”
BackgroundDivya, V., Pushpa, V. L., & Manoj, K. B. (2019) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2019.01.089 · Cited by 11
Aydın, B., Beklen, H., Arğa, K. Y., Bayraklı, F., & Turanlı, B. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01923-2 · Cited by 11
“Palbociclib belongs to the class of pyridopyrimidines and is an orally bioavailable small-molecule inhibitor of CDK4 and CDK6 [91].”
BackgroundRugo, H. S., Im, S., Joy, A. A., Shparyk, Y. V., Walshe, J. M., Sleckman, B. G., Loi, S., Theall, K. P., Kim, S., Huang, X., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.11.005 · Cited by 16
“Palbociclib (Ibrance, Pfizer) is a small molecule inhibitor of CDK4/6 with a high selectivity profile toward CDK4/6 over other CDKs [4,5].”
BackgroundMartínez-Jáñez, N., Bellet, M., Sànchez, L. M. M., Henao, F., Antón-Torres, A., Morales, S. M., Tolosa, P., Gil, V. L. O., Gimeno, T. S., Conejero, R. A., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07287-w · Cited by 12
“Palbociclib was the first CDK 4/6 inhibitor marketed, and together with the other CDK 4/6 inhibitors (ribociclib and abemaciclib), it represents the greatest therapeutic advance in recent years for treatment of HR + /HER2– ABC [4].”
Occhipinti, G., Romagnoli, E., Santoni, M., Cimadamore, A., Sorgentoni, G., Cecati, M., Giulietti, M., Battelli, N., Maccioni, A., Storti, N., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00349 · Cited by 12
“…the perception of CDKs as therapeutic targets in breast cancer following “underwhelming results and unacceptable toxicity were seen with pan-CDK inhibitors such as flavopiridol (alvocidib) in the early 2000s” (Fry et al., 2004; Toogood et al., 2005; Hosford and Miller, 2014; Asghar et al., 2015).”
BackgroundPreclinical discovery and development of abemaciclib used to treat breast cancer
Wright, M. D., & Abraham, J. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1853097 · Cited by 12
“Both palbociclib and ribociclib contain pyrido [2,3-d]pyrimidin-7-one scaffold [32,39,51,82] and employ dyssynchronous dosing due to the DLT of neutropenia.”
BackgroundGajjar, S., & Patel, B. M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173805 · Cited by 11
MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1 -Fusion-Positive Lung Cancer
Iyer, S. R., Odintsov, I., Schoenfeld, A. J., Siau, E., Mattar, M. S., de Stanchina, E., Khodos, I., Drilon, A., Riely, G. J., Ladanyi, M., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0025 · Cited by 11
The novel selective inhibitors of cyclin-dependent kinase 4/6: in vitro and in silico study
Susanti, N. M. P., Kurniawan, F., Damayanti, S., Kartasasmita, R. E., & Tjahjono, D. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-71865-7 · Cited by 10
Tambo, C. S., Tripathi, S. M., Perera, B. G. K., Maly, D. J., Bridges, A. J., Kiss, G., & Rubin, S. M. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00015 · Cited by 13
Schreier, A., Munoz-Arcos, L. S., Soto, A. A., Sparano, J. A., & Anampa, J. D. S. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06574-8 · Cited by 11
“In vitro studies of CDK4/6 inhibitors (CDK4/6i) in human breast cancer cell lines showed hormone positive cell lines to be the most sensitive; moreover, there was synergy when combined with tamoxifen [1, 2].”
BackgroundKitada, K., Pu, F., & Toi, M. (2018) · Oncology Letters · doi:10.3892/ol.2018.9657 · Cited by 10
“PD0332991, a CDK4/6 inhibitor, has been demonstrated to inhibit cell cycle progression and arrest cells in G1 phase (15,16).”
Kumar, A., Singh, A. K., Singh, H., Debbaraman, T., Pathak, P., Naumovich, V., Grishina, M., & Kumar, P. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142053 · Cited by 9
Kurawattimath, V., Wilson, B., Geetha, K. M., & Divekar, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-13721-w · Cited by 11
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients
Poggio, F. B., Lambertini, M., Blondeaux, E., Vaglica, M., Levaggi, A., Pronzato, P., & Mastro, L. D. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1215243 · Cited by 9
A new route for the synthesis of Palbociclib
Li, S., Chen, J., Feng, C., Yang, W., & Ji, M. (2019) · Chemical Papers · doi:10.1007/s11696-019-00841-7 · Cited by 9
Zheng, J., Kong, H., Wilson, J. M., Guo, J., Chang, Y., Yang, M., Xiao, G., & Sun, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093704 · Cited by 9
“Selective CDK inhibitors such as CYC-202 [14] and BMS-387032 [15] targeting CDK2, and PD0332991 [16] targeting CDK4 have been under clinical evaluations.”
BackgroundMessina, C. G. M., Buzzatti, G., Dellepiane, C., Cavo, A., Tolomeo, F., Cattrini, C., & Boccardo, F. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000405 · Cited by 9
Padgaonkar, A., Rechkoblit, O., Carpio, R. V.-D., Pallela, V. R., Subbaiah, D. R. C. V., Cosenza, S. C., Baker, S. J., Reddy, M. V. R., Aggarwal, A. K., & Reddy, E. P. (2018) · Oncotarget · doi:10.18632/oncotarget.26514 · Cited by 10
“Additionally, molecular docking and energy minimization studies with CDK6–ON108110 predict that ON108110 establishes various hydrogen bonds and multiple van der Waals interactions, which were similar to those observed with palbociclib.”
BackgroundInfluentialProductive herpesvirus lytic replication in primary effusion lymphoma cells requires S-phase entry
Hollingworth, R., Stewart, G. S., & Grand, R. J. A. (2020) · Journal of General Virology · doi:10.1099/jgv.0.001444 · Cited by 9
“To confirm that restriction of S- phase entry has a negative effect on viral replication, we next employed a reversible smallmolecule inhibitor of CDK4/6 known as palbociclib that induces a G1 phase arrest in proliferating cells [18, 19].”
BackgroundDiscovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
Xu, Z., Liu, Y., Song, B., Ren, B., Xu, X., Lin, R., Zhu, X., Chen, C., Yang, S., Zhu, Y., et al. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129769 · Cited by 9
Lasnon, C., Morel, A., Aide, N., Silva, A. D., & Emile, G. (2024) · Cancer Imaging · doi:10.1186/s40644-024-00727-2 · Cited by 8
“CdK4/6i prevent DNA replication by blocking progression from the G1 to S phase during cell division and tumor cell proliferation [5, 6], meaning that they arrest tumor growth rather than causing significant tumor cell death.”
BackgroundTraphagen, N. A., Wheeler, E., Li, R., Akhshi, T. K., Ravindranathan, R., Alfieri, C., Lu, F., Ahmed, B., Tewari, A. K., Balk, S. P., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2515790122 · Cited by 9
“For these experiments, we used CDK4/6 inhibition with palbociclib to induce G1 arrest (42 , 43 ).”
Rajesh, A., Havas, A. P., Arnold, R., Lande, K., Lei, X., Li, K. Y., Gandhi, A., Franco, A. C., Woo, S., Lagnado, A. B., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01196-x · Cited by 10
Kinase profiling in early stage drug discovery: sorting things out
Defert, O., & Boland, S. (2015) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2015.10.002 · Cited by 8
CDKL3 is a targetable regulator of cell cycle progression in cancers
Zhang, H., Lin, J., Zheng, S., Ma, L., Pang, Z., Yin, H., Meng, C., Wang, Y., Han, Q. Q., Zhang, X., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178428 · Cited by 8
“Meanwhile, we tested CDK4/6 inhibitor (47) in vitro.”
Mahmoud, H. K., Katouah, H. A., Harras, M. F., & Farghaly, T. A. (2019) · Medicinal Chemistry · doi:10.2174/1573406415666190716153425 · Cited by 8
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
Knudsen, E. S., Witkiewicz, A. K., & Kabraji, S. K. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01431-5 · Cited by 9
“28,29), with similar drugs (ribociclib and abemaciclib) emerging thereafter 3,4,30 .”
One‐Pot Synthesis of 6‐Aminopyrido[2,3‐d]pyrimidin‐7‐ones
Zinchenko, A. M., Музычка, Л. В., Kucher, O. V., Sadkova, I. V., Mykhailiuk, P. K., & Smolii, O. B. (2018) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201801204 · Cited by 7
Mitchell, D. C., Menon, A., & Garner, A. L. (2019) · FEBS Letters · doi:10.1002/1873-3468.13721 · Cited by 8
Ciruelos, E., Vidal, M. J., de Dueñas, E. M., Martínez-Jáñez, N., Fernández, Y., García-Sáenz, J. Á., Murillo, L. S., Carabantes, F., Beliera, A., Fonseca, R., et al. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1784-1 · Cited by 7
“Palbociclib is an orally bioavailable, highly selective inhibitor of cyclin-dependent kinase (CDK)-4 and -6 [9].”
BackgroundGrignard Reagents as Niche Bases in the Synthesis of Pharmaceutically Relevant Molecules
Samineni, R., Eda, V. V. R., Rao, P., Sen, S., & Oruganti, S. (2022) · ChemistrySelect · doi:10.1002/slct.202102853 · Cited by 9
Radwan, M. A. A., Rugaie, O. A., Abdulmonem, W. A., Awad, H., & Zayed, E. M. (2022) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162022040161 · Cited by 7
Pyridine ring as an important scaffold in anticancer drugs
Elagamy, A., Elghoneimy, L. K., & Arafa, R. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91221-1.00004-x · Cited by 10
CDK4/6 inhibitor resistance: A bibliometric analysis
Pang, J., Li, H., & Sheng, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.917707 · Cited by 8
Watanabe, K., Niikura, N., Kikawa, Y., Oba, M. S., Kobayashi, K., Tada, H., Ozaki, S., Toh, U., Yamamoto, Y., Tsuneizumi, M., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06911-5 · Cited by 9
“1 3 breast cancer cell lines with these inhibitors when used in monotherapy, which is synergistic with other endocrine therapies [6].”
BackgroundTorres-Guzmán, R., Chu, S., Velasco, J. A., & Lallena, M. J. (2013) · SLAS DISCOVERY · doi:10.1177/1087057112472539 · Cited by 7
Cabrera, M. C., Díaz‐Cruz, E. S., Kallakury, B., Pishvaian, M. J., Grubbs, C. J., Muccio, D. D., & Furth, P. A. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0532-t · Cited by 8
Wang, X., Wang, H., & Song, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9617 · Cited by 7
“PAL, as a highly selective CDK4/6 inhibitor, can inhibit cells entering the S phase, cell growth and DNA replication (28).”
BackgroundMasuda, N., Kosaka, N., Iwata, H., & Toi, M. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02013-8 · Cited by 7
“Early preclinical studies showed that palbociclib was a potent and highly selective CDK4/6 inhibitor, and that targeting CDK4/6 alone resulted in antitumor activity [13, 14].”
BackgroundA facile synthesis of sulfonate esters from phenols using catalytic KF/NFSI and K2CO3
Dond, B. D., Pansare, D. N., Sarkate, A. P., & Thore, S. N. (2022) · Chemical Papers · doi:10.1007/s11696-022-02585-3 · Cited by 7
Predicting binding energies of CDK6 inhibitors in the hit-to-lead process
Delgado-Soler, L., Aríñez-Soriano, J., Granadino‐Roldán, J. M., & Rubio, J. (2010) · Theoretical Chemistry Accounts · doi:10.1007/s00214-010-0857-9 · Cited by 7
“Moreover, a better selectivity can be achieved when inhibiting these proteins in comparison with other CDKs such as CDK1 or CDK2 [ 4 ], which can be translated to a decrease in undesired side effects.”
BackgroundProgress in the Development of Agents to Control the Cell Cycle
Moriarty, K. J., Koblish, H. K., Johnson, D. L., & Galemmo, R. A. (2007) · Topics in medicinal chemistry · doi:10.1007/7355_2006_006 · Cited by 7
Advances in understanding and targeting eIF4E activity
D’Agostino, S., Davies, C., Powers, M. V., & Clarke, P. A. (2025) · Biochemical Society Transactions · doi:10.1042/bst20241045 · Cited by 7
Rani, N., & Kumar, P. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01258-8 · Cited by 6
“In the present study, the reference drug Palbociclib, a well-known CDK4 inhibitor, has been selected, involving its interaction with the kinase domain at the ATP binding site of CDK4, reducing its kinase activity [20–23].”
Shagufta, Ahmad, I., Bazbouz, L. Z., Nasar, N. A., Ibrahim, F. G., & Alkheder, D. M. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03411-7 · Cited by 6
“The crystal structure and structure-activity relationship analysis of palbociclib indicate that its core skeleton, speci fi cally the pyrido-[2,3-d]pyrimidin-7-one ring, plays a crucial role in determining its speci fi city and activity [16, 27].”
InfluentialActivity of resveratrol triesters against primary acute lymphoblastic leukemia cells
Urbaniak, A. J., Delgado, M., Kacprzak, K. M., & Chambers, T. C. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.066 · Cited by 6
Divya, V., Pushpa, V. L., Sarithamol, S., & Manoj, K. B. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.04.001 · Cited by 8
Selective and novel cyclin-dependent kinases 4 inhibitor: synthesis and biological evaluation
Guo, Q., Li, Y., Zhang, C., Huang, Z. L., Wang, X., Nie, Y., Li, Y., Liu, Y., Yang, S., Xiang, R., et al. (2018) · Medicinal Chemistry Research · doi:10.1007/s00044-018-2180-2 · Cited by 6
Divya, V., Lalithabhai, P. V., & Bahuleyan, M. K. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13452 · Cited by 6
“…& Kawanishi, 2001; Honma et al., 2001; Ikuta et al., 2001; Konstantinidis et al., 1998; Polk et al., 2017; Rader et al., 2013; Shapiro, 2017; Tate et al., 2014; Toogood et al., 2005; VanderWel et al., 2005; Vora et al., 2014; Wang et al., 2004; Zhang et al., 2014) were drawn on 2D sketcher.”
BackgroundPearson, A. D. J., Chi, S. N., Laetscht, T. W., Marshall, L. V., Raetz, E. A., George, R. E., Chesler, L., Karres, D., Scobie, N., Knoderer, H. M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115629 · Cited by 6
Choosing the right animal model for sarcoma research
Remiszewski, P., Siedlecki, E., Wełniak-Kamińska, M., Mikula, M., & Czarnecka, A. M. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-06013-z · Cited by 5
“More-over, in myxoid liposarcoma, the first-generation CDK4/6 inhibitor PD-0332991 (palbociclib) was shown to produce deep, durable G1 arrest and tumour regression across multiple human tumour xenografts, with schedule-dependent effects related to the duration of target suppression [ 61].”
Wang, Y., Nan, X., Duan, Y., Wang, Q., Liang, Z., & Yin, H. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117870 · Cited by 5
Kahraman, S., Erul, E., Gümüşay, Ö., Güven, D. C., Aksoy, S., Başaran, G., Seyyar, M., Şahin, E., Cabuk, D., Bayram, E., et al. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.03.003 · Cited by 5
Zhang, Y., Luo, Z., Jiang, Y., Zheng, L. T., Ma, L., Zheng, Y., Zou, M., Kong, L., & Wang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117495 · Cited by 5
Novel Small Molecule Inhibitors of Cyclin-dependent Kinases as Anticancer Agents
Srivastava, N., & Saxena, A. K. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673331685241205180307 · Cited by 8
CDK4/6 are necessary for UCP1-mediated thermogenesis of white adipose tissue
Portales, A. E., Miguel, I., Rodriguez, M. J., Novaro, V., Gambaro, S. E., & Giovambattista, A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121652 · Cited by 6
Ploumaki, I., Triantafyllou, E., Koumprentziotis, I., Karampinos, K. I., Drougkas, K., Karavolias, I., & Kotteas, E. A. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.01.002 · Cited by 6
Fang, Y., Lv, X., Li, G., Wang, P., Zhang, L., Wang, R., Jia, L., & Liang, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-92992-9 · Cited by 11
“Among these selective inhibitors, palbociclib was the most widely investigated and has been evaluated both in vitro and in vivo 49,50 .”
Heo, M. H., Kim, H. K., Lee, H., Kim, J., Ahn, J., Im, Y., & Park, Y. H. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.226 · Cited by 5
“Palbociclib is an orally bioavailable selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) that prevents DNA synthesis by blocking progression of the cell cycle from G1 to S phase [8,9].”
BackgroundA SAR and QSAR study on cyclin dependent kinase 4 inhibitors using machine learning methods
Pang, X., Zhao, Y., Guo, L., Liu, J., & Yan, A. (2023) · Digital Discovery · doi:10.1039/d2dd00143h · Cited by 7
Palbociclib (Ibrance): The First‐in‐Class CDK4/6 Inhibitor for Breast Cancer
Toogood, P. L., & Ide, N. D. (2015) · Wiley eBooks · doi:10.1002/9781118819951.ch9 · Cited by 6
Self-citationWu, P., & Choudhary, A. (2018) · Wiley eBooks · doi:10.1002/9783527808694.ch3 · Cited by 5
The kinase inhibitor Palbociclib is a potent and specific RNA-binding moleculePreprint
Shortridge, M. D., Vidalala, V., & Varani, G. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.20.477126 · Cited by 5
Advances in combination therapy for the treatment of estrogen receptor positive breast cancer
Liu, L., Zhao, Z., Zou, F., Liu, W., & Lu, Y. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111451 · Cited by 6
Metadata
- Authors
- Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., Brodfuehrer, J., Choi, C., Barvian, M. R., & Fry, D. W.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Toogood, Peter L.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-03-02
- Volume
- 48
- Issue
- 7
- Pages
- 2388-2406
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1985389450
- Cited by
- 513
- References
- 50
- Citations by year
- 2026: 23 · 2025: 41 · 2024: 20 · 2023: 25 · 2022: 38 · 2021: 32 · 2020: 32 · 2019: 30 · 2018: 44 · 2017: 42 · 2016: 34 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 17
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDK4/6, CDK4/6 inhibitors, kinase selectivity, G1 cell cycle arrest, palbociclib, small-molecule kinase inhibitors, anticancer drug candidates, pharmacokinetics
- MeSH terms
- Animals, Antineoplastic Agents, Biological Availability, Humans, Male, Piperazines, Proto-Oncogene Proteins, Pyridines, Pyrimidines, Structure-Activity Relationship, Thymidine, G1 Phase, Rats, Sprague-Dawley, Cyclin-Dependent Kinases, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.